Kano H, Ichihara E, Watanabe H, Nishii K, et al. SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naive ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer. Mol Cancer Ther 2021 Jun 22. pii: 1535-7163.MCT-20-0965.
PMID: 34158345